Get the Stockscreener App
1.67
2.14%
0.035
After Hours:
1.60
-0.07
-4.19%
Cocrystal Pharma Inc stock is traded at $1.67, with a volume of 21,426.
It is up +2.14% in the last 24 hours and down -10.22% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
See More
Previous Close:
$1.635
Open:
$1.6
24h Volume:
21,426
Relative Volume:
0.48
Market Cap:
$16.99M
Revenue:
-
Net Income/Loss:
$-17.93M
P/E Ratio:
-0.9435
EPS:
-1.77
Net Cash Flow:
$-14.28M
1W Performance:
-5.11%
1M Performance:
-10.22%
6M Performance:
+0.00%
1Y Performance:
+13.61%
1-Day Range:
$1.58
$1.70
1-Week Range:
$1.5767
$1.80
52-Week Range:
$1.35
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.67 | 16.99M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
Life Sciences Investor Forum Agenda Announced for March 13th - Yahoo Finance
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire
Kaltura to Host 2025 Investor Event - The Manila Times
Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan
Aptorum Gr Stock Price, Quotes and Forecasts | NASDAQ:APM - Benzinga
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - ACCESS Newswire
New Information Reveals Opportunity in Volatility -- Featured Research on Norsk Hydro, Paragon Offshore, Pure Biosciences and Cocrystal Pharma - ACCESS Newswire
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater
An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice
Cocrystal Pharma Extends Phase 2a Influenza Drug Study Amid Lower Infection Rates, Stock Near 52-Week High - HPBL
Influenza Clinical and Non-Clinical Studies, Key Companies, - openPR
What is Northland Capmk’s Forecast for CECO FY2024 Earnings? - Defense World
HC Wainwright Forecasts Higher Earnings for Cocrystal Pharma - Defense World
Influenza Pipeline Insights, Clinical Trials Analysis, Emerging Therapies and Companies | DelveInsight - EIN News
**Cocrystal Pharma, Inc. Presents Corporate Update to Investment Community** - Defense World
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Cocrystal Pharma Engages Investors with Limited Disclosure - TipRanks
Cocrystal Pharma Reports Positive Phase 1 Results with Oral Pan-Viral Protease Inhibitor CDI-988 for Norovirus and Coronavirus Infections - Defense World
COCP: Phase 2a Trial of CC-42344 Extended - Smartkarma
COCP: Phase 2a Trial of CC-42344 Extended… - Zacks Small Cap Research
Cocrystal Pharma Reports Positive Phase 1 Study Results - TipRanks
Cocrystal Pharma Reports Phase 1 Results with Oral, - GlobeNewswire
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections - Yahoo Finance
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial - Yahoo Finance
CLS Holdings USA, Inc. Executes Agreement to Amend Convertible Debentures - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Growth in Short Interest - Defense World
BRC Inc. (NYSE: BRCC) Amends Credit Agreements and Enters into $40 Million Term Loan Facility - Defense World
A SPAC III Acquisition Corp Announces Agreement with HD Education Group Limited - Defense World
Supermarket Income REIT (OTCMKTS:SUPIF) Shares Up 0.7% – Should You Buy? - Defense World
Cornish Metals (LON:CUSN) Shares Up 1.1% – What’s Next? - Defense World
Greenwave Technology Solutions (NASDAQ:GWAV) Stock Price Down 3.9% – Here’s What Happened - Defense World
Cocrystal Pharma, Inc. to Extend Phase 2a Influenza Challenge Study with Oral PB2 Inhibitor CC-42344 - Marketscreener.com
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extens - GuruFocus.com
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement - GuruFocus.com
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
Cocrystal stock plunges 40% on influenza drug update - MSN
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
Cocrystal stock plunges 40% on influenza drug update (COCP:NASDAQ) - Seeking Alpha
US Stocks Open Higher; House Prices Increase In October - Benzinga
Equitable Holdings, Inc. (NYSE: EQH): Insider Trades, Institutional Moves, and Market Momentum - HPBL
Alexander, Inc. (NYSE: ALX): A Deep Dive into Rising Short Interest, Dividends, and Institutional Activity - HPBL
EQT Corporation: A Deep Dive into the Natural Gas Giant Performance and Market Insights – News - HPBL
Cocrystal Pharma Extends Enrollment for Influenza Study - TipRanks
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):